News

HLL Biotech Ltd (HBL), a subsidiary of HLL Lifecare Ltd (HLL) has entered into a long term agreement with Biological E Limited (BE), Hyderabad for two vaccines namely the Liquid Pentavalent (DPT-HepB-Hib) vaccine and Hepatitis B vaccine.

Under the agreement, BE will conduct scale-to-scale transfer of the technology for Hepatitis B vaccine, which will help HBL to manufacture the Vaccine at Integrated Vaccines Complex (IVC), Chengalpattu on a fast track mode. The other area of co-operation is in the field of Liquid Pentavalent vaccine. BE will supply the Pentavalent vaccine bulk to HBL to be filled and packed at IVC, by which HBL will be able to enter in to the market with Pentavalent vaccine in the near future.

The agreement was signed between Dr. M. Ayyappan, Chairman HBL and Mr. Narender Dev Mantena, Senior Vice President, BE in the presence of Honourable Secretary, Mr. Keshav Desiraju Ministry of Health and Family Welfare, Government of India at Nirman Bhawan, New Delhi.

Dr. M. Ayyappan, Chairman HBL said “our agreement with BE will make available cost effective Liquid pentavalent vaccine in our country”.This public-private partnership will primarily strengthen the Immunization program of India”.

“Government of India has recently introduced Liquid Pentavalent vaccine (DPT-Hep B, Hib) in the immunization program as a pilot scale study. By this vaccination, the child will get protection from five diseases i.e., Diphtheria, Pertussis (whooping cough), Tetanus, Hepatitis B infection and the meningitis by Haemophilus influenzae type B by a single injection. As on date, BE is one of the three liquid Pentavalent vaccine manufacturers prequalified by WHO for manufacture and supply liquid Pentavalent combination – liquid (DPT-HepB-Hib), added Dr. M. Ayyappan.